|
|
Volumn 343, Issue , 2011, Pages
|
|
Merck pays $1bn penalty in relation to promotion of rofecoxib.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CYCLOOXYGENASE 2 INHIBITOR;
LACTONE;
ROFECOXIB;
SULFONE;
DRUG INDUSTRY;
ECONOMICS;
FINANCIAL MANAGEMENT;
HUMAN;
LEGAL ASPECT;
NOTE;
PROFESSIONAL MISCONDUCT;
UNITED STATES;
CYCLOOXYGENASE 2 INHIBITORS;
DRUG INDUSTRY;
HUMANS;
LACTONES;
MARKETING OF HEALTH SERVICES;
PROFESSIONAL MISCONDUCT;
SULFONES;
UNITED STATES;
|
|
EID: 84855566038
PISSN: None
EISSN: 14685833
Source Type: Journal
DOI: 10.1136/bmj.d7702 Document Type: Note |
|
Times cited : (9)
|
|
References (0)
|
